Hypoestoxide (1, Scheme 1) was isolated from the tropical shrub Hypoestes rosea, found in the Nigerian rainforests. [1] Extracts from these shrubs have been used in folk medicine for generations, to treat various skin rashes and infections. Hypoestoxide has been shown in recent studies to exhibit promising anticancer, [2] antimalarial, [3] and anti-inflammatory activity.[4] Our interest stems primarily from encouraging antiangiogenic activities, in which hypoestoxide was shown to inhibit the growth of a number of human and murine tumor cell lines in vivo. In terms of angiogenesis, hypoestoxide inhibited vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Hypoestoxide is a bicyclo[9.3.1]pentadecane diterpenoid containing a rigid "inside-outside" ring system decorated with an exocyclic enone, two epoxide moieties, and an acetate group. This rare ring system has also been described for the verticillanes, [5] of which verticillol (3, Scheme 1) [6] is the most well known. As a more oxygenated variant of verticillol, it is tempting to propose that hypoestoxide is formed from the same common cationic precursor (5) as both verticillol [7] and taxol (4), [8] which in turn originates from consecutive cyclizations of geranylgeranyl pyrophosphate. In the case of verticillol, the cation 5 is trapped with water, whereas, for taxol and hypoestoxide, it undergoes endocyclic and exocyclic eliminations, followed by oxygenations and cyclizations. As part of our efforts to evaluate the molecular mechanisms [9] of promising natural product anticancer agents we have focused our investigations on hypoestoxide and the verticillanes.Several factors needed to be considered before beginning our synthetic efforts. First, for a trans-[9.3.1]bicyclic framework, two different atropisomers are possible. Calculations (B3LYP/6-311 + G(d,p)) indicated that hypoestoxide is 4.1 kcal mol À1 more stable than the atropisomer (2). Therefore, we imagined that any such macrocyclization would preferentially form the naturally occurring atropisomer. In addition, the energy change attributed to the process of interconverting hypoestoxide and the atropisomer was estimated to be 65 kcal mol À1 . Diene 6 seemed an ideal target because it allows access to all known verticillanes, and we attempted its synthesis using a conformationally controlled ring-closing metathesis (Scheme 2). This diene provides four different options for ring-closing metathesis. Both the C5=C6 and C9=C10 bonds can originate from either a standard monosubstituted carbene or, alternatively, from a disubstituted carbene, such as 7, which can be accessed by relay metathesis.[10] Our analysis suggested that, in closing the macrocycle, it would be advantageous to bring together a more-substituted carbene with a less-hindered terminus to minimize competing dimerization pathways. We further postulated that ruthenium carbene 7 (C5=C6 disconnection) would be the better candidate for macrocyclization, since the Scheme 1. Hypoestoxide and verticillol.Scheme 2. Retr...